Kura Oncology (NASDAQ:KURA) Shares Gap Up – Should You Buy?

Kura Oncology, Inc. (NASDAQ:KURA) gapped up before the market opened on Tuesday . The stock had previously closed at $17.56, but opened at $18.30. Kura Oncology shares last traded at $18.68, with a volume of 40,820 shares trading hands.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and cut their target price for the company from $26.00 to $19.00 in a research report on Monday, October 14th. UBS Group started coverage on shares of Kura Oncology in a research note on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective on the stock. Wedbush reissued an “outperform” rating and issued a $37.00 target price on shares of Kura Oncology in a research report on Monday, November 4th. Lifesci Capital raised shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Kura Oncology currently has an average rating of “Moderate Buy” and a consensus price target of $28.83.

Kura Oncology Trading Down 4.4 %

The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm’s 50 day moving average is $18.63 and its two-hundred day moving average is $19.97. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of -7.52 and a beta of 0.86.

Institutional Trading of Kura Oncology

A number of institutional investors and hedge funds have recently made changes to their positions in KURA. Vanguard Group Inc. grew its stake in Kura Oncology by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after buying an additional 28,212 shares during the last quarter. Avoro Capital Advisors LLC boosted its holdings in shares of Kura Oncology by 29.2% during the first quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after acquiring an additional 870,000 shares during the period. Armistice Capital LLC grew its position in shares of Kura Oncology by 14.7% during the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after acquiring an additional 302,000 shares during the last quarter. Artal Group S.A. increased its holdings in shares of Kura Oncology by 8.6% in the 1st quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock worth $40,951,000 after acquiring an additional 151,828 shares during the period. Finally, Assenagon Asset Management S.A. lifted its position in Kura Oncology by 50.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock valued at $35,653,000 after purchasing an additional 577,732 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.